DarioHealth Presents New Study Demonstrating Significant Clinical Impact Of Personalized Digital Interventions Based On Real-Time Data

New Study Presented at American Association of Diabetes Care and Education Specialists Annual Conference Highlights the Clinical Strength of Dario’s AI-Driven Journey Engine

Research Demonstrates a 19% improvement in blood glucose readings

DarioHealth Corp. a pioneer in the global digital therapeutics market, announced a new study at the American Association of Diabetes Care and Education Specialists (ADCES) annual conference demonstrating the impact of Dario’s intelligent personalization platform.

Recommended AI News: Insight Unites With Women In Cloud To Accelerate Workplace Diversity In Technology

Dario’s latest presentation examined the impact of personalized clinical interventions delivered in real-time through the company’s digital therapeutics platform. To understand the potential impact, the study tracked a group of 3,609 Dario members including people with Type 2 diabetes, both insulin and non-insulin dependent, with recent clusters of high blood glucose readings, an indicator of poor health behaviors.

The test group received dynamically personalized communications that consisted of clinical, behavioral and educational content triggered by real-time member data as part of a digital clinical intervention. The personalized messages, developed by clinical professionals, aim to help members improve their health behaviors by raising awareness of medication and lifestyle behaviors, and included educational content and decision support. The ability to deliver these personalized messages at clinically relevant moments, using real-time member data, resulted in better clinical outcomes for the test group.

Recommended AI News: Merkle Collaborates With Magnite On Merkury Identity Resolution Platform

The research results demonstrated significant reduction in high blood glucose readings versus control group:

•   19% difference in reduction for all test group members
•   18% difference in reduction in test group members with Type 2 diabetes
•   42% difference in reduction in a sub-set of test group members with Type 2 diabetes who were not using insulin treatment

Importantly, the study looked at the test group before and after the personalized intervention, demonstrating a significant difference in the following months. For the Type 2 non-insulin users in particular, the results indicate personalized communications are effectively influencing positive lifestyle behavior change.

“Digital therapeutics delivered with the power of a real-time digital journeys offer a unique opportunity to improve health with the delivery of timely, relevant interventions. Personalizing those interventions to help address poor health behaviors offers great promise to improve self-health management and long-term clinical outcomes,” said Yifat Hershcovitz, Scientific and Clinical Director of DarioHealth and lead author of the study.

“Digital therapeutics can play a key role in driving meaningful behavior change when the member experience is truly tailored to follow each person’s unique journey. This research is another example of how Dario is able to adapt and respond to our members using a combination of real-time data and clinically-guided, highly personalized interventions to drive healthier behaviors and deliver better results,” said Omar Manejwala, M.D., Chief Medical Officer, DarioHealth.

Recommended AI News: Titan Launches First Actively Managed Portfolio Of Cryptocurrency Assets Available To US Investors